FALCON trial of fulvestran for advanced breast cancer: subgroup analysis and overall survival

FALCON trial of fulvestran for advanced breast cancer: subgroup analysis and overall survival

VJOncology

3 years
332 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Matthew Ellis, MB, BChir, PhD, FRCP of Baylor College of Medicine, Houston, TX discusses take-home messages from the Phase III FALCON randomized trial of fulvestran versus anastrozole for hormone receptor-positive advanced breast cancer (NCT01602380). Prof. Ellis explains that one of the take-home messages comes from a subgroup analysis. Patients with hormone receptor-positive advanced breast cancer form a very heterogenous group; a typical patient on the FALCON trial had non-visceral disease. In this group, the advantage for fulvestran seems more dramatic as Prof. Ellis explains. Further, the overall survival (OS) data for using fulvestran upfront is not known yet; there is a hypothesis from an earlier, smaller, open-label study suggesting that fulvestran could be associated with an OS advantage if used frontline but the study was not big enough to be definitive. According to Prof. Ellis, we will know about OS in around 18 months to two years when the study is fully matured. Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.
Up Next Autoplay
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Category: Ovarian Cancer
19 Views
SeattleCCA 4 days
CDX-1140 Shows Clinical and Biological Efficacy in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Studies
CDX-1140 Shows Clinical and Biological Efficacy in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Studies
Category: Immunotherapy
11 Views
Cancer-News 4 days
Immune and Circulating Tumor DNA Profiling #NSCLC @MDAndersonNews
Immune and Circulating Tumor DNA Profiling #NSCLC @MDAndersonNews
Category: Non-Small Cell Lung Cancer
7 Views
MD Anderson 4 days
KY1044 Targets ICOS @kymabltd @rcasainson
KY1044 Targets ICOS @kymabltd @rcasainson
Category: Other
3 Views
Cancer-News 4 days
What Mechanism of Action is the Most Relevant for Targeting ICOS? @rcasainson @KymabLtd
What Mechanism of Action is the Most Relevant for Targeting ICOS? @rcasainson @KymabLtd
Category: Other
6 Views
Cancer-News 4 days
DNA Profiling Following Radiation Treatment in #NSCLC @MDAndersonNews
DNA Profiling Following Radiation Treatment in #NSCLC @MDAndersonNews
Category: Non-Small Cell Lung Cancer
24 Views
MD Anderson 4 days
New Findings for KY1044 Anti-ICOS Program at the #CICON2019 Annual Meeting @kymabltd @rcasainson
New Findings for KY1044 Anti-ICOS Program at the #CICON2019 Annual Meeting @kymabltd @rcasainson
Category: Other
12 Views
Cancer-News 4 days
Ideal Management of Steroid Refractory in GVHD @OSUCCC_James
Ideal Management of Steroid Refractory in GVHD @OSUCCC_James
Category: News
8 Views
OSUCCC 4 days
Phase 3 NINLAROTM (ixazomib) Trial as the Primary Endpoint of First-Line Maintenance Therapy in Multiple Myeloma Patients not Treated with Stem Cell Transplantation #MM
Phase 3 NINLAROTM (ixazomib) Trial as the Primary Endpoint of First-Line Maintenance Therapy in Multiple Myeloma Patients not Treated with Stem Cell Transplantation #MM
Category: Multiple Myeloma
12 Views
Cancer-News 5 days
Improve Readiness for Stem Cell Transplant Recipients @OSUCCC_James
Improve Readiness for Stem Cell Transplant Recipients @OSUCCC_James
Category: News
17 Views
OSUCCC 5 days